Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 26, 2019updated 23 Dec 2019 8:27am

Medicines Company’s inclisiran meets all endpoints in ORION-10 trial

The Medicines Company has reported positive results from the Phase III ORION-10 clinical trial, where cholesterol-lowering drug inclisiran met all primary and secondary endpoints in atherosclerotic cardiovascular disease (ASCVD) patients.

The Medicines Company has reported positive results from the Phase III ORION-10 clinical trial, where cholesterol-lowering drug inclisiran met all primary and secondary endpoints in atherosclerotic cardiovascular disease (ASCVD) patients.

Inclisiran is a small-interfering RNA (siRNA) therapy that uses the body’s RNA interference process to prevent the production of the PCSK9 protein in the liver.

The mechanism is said to improve the liver’s ability to remove and reduce the levels of low-density lipoprotein cholesterol (LDL-C) in the blood.

In the ORION-10 study, 300mg inclisiran sodium’s safety, efficacy and tolerability were evaluated in 1,561 ASCVD patients with increased LDL-C even after receiving a maximum tolerated dose of LDL-C-lowering drugs.

The trial was performed at 145 US sites and involved subcutaneous administration of the drug.

The primary endpoints were a percentage change in LDL-C to day 510 and time-adjusted percentage change in LDL-C after day 90 and up to day 540.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The trial’s key secondary endpoints also included the mean absolute change at day 510, the average absolute decrease from day 90 and up to day 540, and in other lipids and lipoprotein changes.

According to the top-line data, inclisiran showed a safety, efficacy and tolerability profile that was at least as favourable as that found in ORION-11, which is a separate Phase III trial of the drug candidate conducted in ASCVD patients.

In ORION-10, investigators did not report any treatment-related liver or renal laboratory abnormalities.

The Medicines Company CEO Mark Timney said: “The results seen in ORION-10 again demonstrate inclisiran’s outstanding efficacy, tolerability and safety.

“This is further validation of the potential of this first and only investigational cholesterol-lowering therapy in the siRNA class to transform the treatment of cardiovascular disease for millions of people with ASCVD.”

The company plans to submit applications seeking regulatory approval for inclisiran in the US and Europe in the fourth quarter of this year and the first quarter of next year, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU